Document is current
Any future updates will be listed below
-
Authors
Freeman, Ciara L. https://orcid.org/0000-0002-0662-6480
Pararajalingam, Prasath
Jin, Ling
Balasubramanian, Sriram
Jiang, Aixiang https://orcid.org/0000-0002-6153-7595
Xu, Wendan
Grau, Michael
Zapukhlyak, Myroslav
Boyle, Merrill
Hodkinson, Brendan
Schaffer, Michael
Enny, Christopher
Deshpande, Sanjay
Sun, Steven
Vermeulen, Jessica
Morin, Ryan D. https://orcid.org/0000-0003-2932-7800
Scott, David W.
Lenz, Georg https://orcid.org/0000-0002-4728-1693
- License Information
-
More Information
Article History
Received: 5 November 2021
Revised: 6 July 2022
Accepted: 14 July 2022
First Online: 13 August 2022
Competing interests
: CLF received honoraria from Seattle Genetics, Incyte, Janssen, Amgen, Celgene, AbbVie, and Sanofi and research funding from Janssen, Roche, and Teva. SB, BH, MS, CE, SD, SS, and JV are employees of Janssen Research & Development; SB, MS, CE, SD, SS, and JV also have equity ownership with the company. DWS has patents, one of which is licensed to NanoString Technologies, has served as a consultant for AstraZeneca, AbbVie, and Celgene, and received research funding from NanoString Technologies, Janssen, Celgene, and Roche. GL received research funding from Agios, Aquinox, Janssen, MorphoSys, Celgene, Roche, AstraZeneca, Gilead, Bayer, Novartis, and Verastem, and honoraria from Janssen, Celgene, Roche, AstraZeneca, Gilead, Bayer, Novartis, Bristol Myers Squibb, and Hexal, and has served on advisory boards for Janssen, Celgene, Roche, AstraZeneca, Gilead, Bayer, Novartis, Bristol Myers Squibb, Hexal, AbbVie, Genmab, MorphoSys, NanoString, and Takeda. PP, LJ, AJ, WX, MG, MZ, MB, and RDM have no conflicts of interest to disclose.
